Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve functional outcomes of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19, today announces the appointment of Doctor Yann Meunier and Professor Bernard Lévy to its scientific committee .